Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics

Jason Roh

Harvard Medical School

Robert Kitchen

Harvard Medical School <https://orcid.org/0000-0003-1443-8559>

J Sawalla Guseh

Massachusetts General Hospital

Jenna McNeill

Massachusetts General Hospital

Malika Aid

Beth Israel Deaconess Medical Center BIDMC

Amanda Martinot

Tufts University <https://orcid.org/0000-0001-6237-6191>

Andy Yu

Massachusetts General Hospital

Colin Platt

Massachusetts General Hospital

James Rhee

Massachusetts General Hospital

Brittany Weber

Brigham and Women's Hospital

Lena Trager

Massachusetts General Hospital

Margaret Hastings

Massachusetts General Hospital

Sarah Ducat

Tufts University <https://orcid.org/0000-0002-5285-7642>

Peng Xia

Massachusetts General Hospital

Claire Castro

Massachusetts General Hospital

Bjarni Atlason

Massachusetts General Hospital

Timothy Churchill

Massachusetts General Hospital

Marcelo Di Carli

Brigham and Women's Hospital

Patrick Ellinor

The Broad Institute of MIT and Harvard <https://orcid.org/0000-0002-2067-0533>

Dan Barouch

Beth Israel Deaconess Medical Center <https://orcid.org/0000-0001-5127-4659>

Jennifer Ho

Massachusetts General Hospital

Anthony Rosenzweig (✉ ROSENZWE@HELIX.MGH.HARVARD.EDU)

Massachusetts General Hospital

Article

Keywords: COVID-19, cardiovascular complications, disease severity, mortality

Posted Date: June 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-539712/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Cardiovascular complications are common in COVID-19 and strongly associated with disease severity and mortality. However, the mechanisms driving cardiac injury and failure in COVID-19 are largely unknown. We performed plasma proteomics on 80 COVID-19 patients and controls, grouped according to disease severity and cardiac involvement. Findings were validated in 305 independent COVID-19 patients and investigated in an animal model. Here we show that senescence-associated secretory proteins, markers of biological aging, strongly associate with disease severity and cardiac involvement even in age-matched cohorts. FSTL3, an indicator of Activin/TGF β signaling, was the most significantly upregulated protein associated with the heart failure biomarker, NTproBNP ($\beta = 0.4$; $p_{\text{adj}} = 4.6 \times 10^{-7}$), while ADAMTS13, a vWF-cleaving protease whose loss-of-function causes microvascular thrombosis, was the most downregulated protein associated with myocardial injury ($\beta = -0.4$; $p_{\text{adj}} = 8 \times 10^{-7}$). Mendelian randomization supported a causal role for ADAMTS13 in myocardial injury. These data provide important new insights into the pathophysiology of COVID-19 cardiovascular complications with therapeutic implications.

Introduction

Since its discovery in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in ~ 160 million cases of coronavirus disease 2019 (COVID-19) and nearly 3.3 million deaths globally.¹

Although viral pneumonia is the predominant clinical manifestation of severe COVID-19, cardiovascular complications occur frequently and are independently associated with morbidity and mortality. Among hospitalized COVID-19 patients, myocardial injury occurs in ~ 20–62%,^{2–6} vascular thrombosis in ~ 16%,⁷ and acute heart failure in ~ 2.5%.⁸ Acute heart failure in COVID-19 often occurs in those without preexisting heart failure, and is associated with mortality rates approaching 47%.⁸ Myocardial injury, the most common cardiac complication in COVID-19, also remains a strong predictor for adverse outcomes and is associated with ≥ 2 -fold increase of in-hospital mortality.⁶

There are multiple potential contributors to cardiac injury and dysfunction in COVID-19.^{9–13} While myocardial injury, indicated by elevations in circulating cardiac troponins, is common in COVID-19,^{2–5,14,15} both Type I myocardial infarction caused by epicardial coronary artery occlusion and myocarditis appear rare,^{11,12} suggesting other mechanisms drive most COVID-19-related cardiac injury and failure. We systematically examined circulating proteins in controls and COVID-19 patients to identify potential drivers of cardiovascular complications. These studies support inferences into the pathogenesis of COVID-19-induced cardiac injury and implicate pathways amenable to intervention in this process.

Results

Characteristics of discovery study participants

The cohort for the case control plasma proteomics discovery study had a mean age of 64 years and 41% women (Table 1). There were no significant differences in age or sex between COVID-19 patients and controls, though controls included more white subjects and there was a non-significant trend of higher age in moderate COVID-19 patients with cardiac involvement due to limited samples available for matching. Controls had higher body mass index, but less coronary artery disease, diabetes, and cancer. There were no differences in baseline hypertension, hyperlipidemia, myocardial infarction, stroke, liver or pulmonary disease, except for a higher prevalence of obstructive sleep apnea in controls. Among moderate COVID-19 patients, those with cardiac involvement had more chronic kidney disease and baseline anticoagulation use. In severe COVID-19 patients, cancer was more prevalent in those with higher levels of cardiac involvement. Cardiac involvement in COVID-19 patients was generally associated with higher high-sensitivity cardiac troponin T (hsTnT), N-terminal pro-B natriuretic peptide (NTproBNP), C-reactive protein (CRP), and D-dimer levels (Supplementary Table 1). There was no significant difference in PE and DVT, although event rates were relatively low. Severe COVID-19 patients with high degrees of cardiac involvement had the highest in-hospital mortality (33%) (Supplementary Table 1).

Plasma proteins associated with senescence and microvascular inflammation increase with worsening COVID-19 severity and cardiac involvement

To first determine if the plasma proteomic profiles distinguish subjects according to COVID-19 disease severity and/or cardiac involvement, we performed unsupervised principal component analysis in the discovery cohort. Strikingly, the first principal component (PC1), representing the maximum variance in the dataset, clustered most subjects into their pre-specified group (Fig. 1a). This suggests the plasma proteome not only distinguishes between subjects with and without COVID-19, but can also accurately discriminate among varying COVID-19 disease severity and cardiac involvement. Notably, cardiac TnT and NTproBNP, proteins used to assign subjects to the different groups, were not the dominant proteins driving PC1 (Supplementary Fig. 2). Rather, enrichment analysis of PC1 proteins identified innate immune responses, senescence, RNA processing, and cell injury as the most significant biological processes that discriminate among these five groups (Fig. 1b; Supplementary Table 2).

Interestingly, despite groups being age-matched, proteins in a senescence-associated secretory phenotype (SASP-1) set (Supplementary Table 3)¹⁶, markers of biological aging, emerged as the most upregulated process (normalized enrichment score [NES] = 2.2; p_{adj} =0.01) (Supplementary Table 2). To confirm this finding, an additional SASP-2 set was generated from a literature search of all published SASP proteins (Supplementary Table 3) and was also highly enriched in PC1 (NES = 2.0; p_{adj} =0.01). Subgroup analyses consistently showed SASP-2 to be the most significantly upregulated process associated with cardiac involvement in both moderate (NES = 1.6, p_{adj} =0.03) and severe (NES = 1.7, p_{adj} =0.02) COVID-19 (Supplementary Tables 4–7). In an independent validation cohort of 305 COVID-19 patients, the two SASP protein sets were the pathways most significantly associated with disease severity (Fig. 1b; Supplementary Table 8). Interestingly, in transcriptional profiles of lungs from hamsters infected with

SARS-CoV2, we also saw marked enrichment of both SASP-1 (NES = 1.8; FDR q-value = 0.001) and SASP-2 (NES = 2.2; FDR q-value < 0.001) compared to age-matched non-infected controls (Fig. 1c, Supplementary Table 9), suggesting that this age-related cellular senescence profile is induced by COVID-19.

To identify circulating proteins associated with COVID-19 infection, we next compared plasma proteomes of COVID-19 patients (n = 54) to non-infected controls (n = 26). Consistent with the microvascular pathology seen in COVID-19,^{9-13,17} plasma proteomic signals strongly suggested endothelial injury. The most upregulated plasma proteins in COVID-19 were extracellular histones (Fig. 2a, Supplementary Table 10), markers of neutrophil extracellular traps implicated in COVID-19-related microvascular inflammation and thrombosis.¹⁷ Furthermore, von Willebrand Factor (vWF), a clotting factor secreted by activated endothelial cells, was one of the most significantly elevated circulating proteins in COVID-19 (341% higher; $p_{\text{adj}}=8.3 \times 10^{-18}$, Fig. 2a, Supplementary Table 10).

To identify proteins correlated with COVID-19 severity, we compared patients with moderate (n = 25) versus severe (n = 29) COVID-19 and found 171 plasma proteins differentially expressed between the groups (Fig. 2b, Supplementary Table 11). The most significantly increased protein in severe COVID-19 was regenerating islet-derived protein 3 gamma (REG3G; 353% higher; $p_{\text{adj}}=1.4 \times 10^{-5}$), an antimicrobial protein secreted by pulmonary and gut epithelium.^{18,19} Interestingly, two of the 10 most significantly downregulated proteins were neural cell adhesion molecules (NCAM1 and NCAM2), which were 38% and 34% lower in patients with severe COVID-19, respectively ($p_{\text{adj}}=6.6 \times 10^{-5}$ and 9.0×10^{-4}). NCAMs regulate axonal outgrowth and olfactory development,²⁰ raising the possibility of a role in the anosmia phenotype sometimes seen in COVID-19. The most striking finding, however, was a 44% reduction in ADAMTS13 (A Disintegrin And Metalloproteinase with a Thrombospondin type I motif, member 13), which was the most significantly downregulated of the 4996 protein analytes in severe COVID-19 ($p_{\text{adj}}=1.4 \times 10^{-5}$). ADAMTS13 is a secreted protease that inhibits thrombosis by cleaving vWF multimers, and its deficiency is a known cause of spontaneous microvascular clot formation and thrombotic thrombocytopenia purpura (TTP).²¹ vWF/ADAMTS13 ratios progressively increased with worsening COVID-19 severity (Supplementary Fig. 3), suggesting that a deficiency in ADAMTS13 levels relative to its known substrate occurs with increased COVID-19 severity. Furthermore, ADAMTS13 levels inversely correlated with clinical D-dimer levels in COVID-19 patients ($r=-0.7$, $p < 0.001$, Supplementary Fig. 4), suggesting that the overall thrombotic burden in COVID-19 patients is higher in those patients with lower ADAMTS13 levels.

ADAMTS13 deficiency in COVID-19 related myocardial injury

To gain insight into the drivers of myocardial injury in COVID-19, we regressed our datasets on cardiac troponin (TnT) SOMAmer levels, which strongly correlated with clinical hsTnT concentrations ($r = 0.8$, $p = 3.1 \times 10^{-13}$, Supplementary Fig. 5). 1,143 proteins differed significantly after regression on TnT (Fig. 3a, Supplementary Table 12). The proteins with the most significant positive association with cardiac TnT were mostly intracellular myocyte proteins, likely reflecting myocardial necrosis. Interestingly, the protein with the most significant negative association with cardiac TnT was ADAMTS13 (β coefficient= -0.4;

$p_{\text{adj}}=8 \times 10^{-7}$). Given the marked and progressive decline in ADAMTS13 levels observed with increasing cardiac involvement along with its strong correlation with TnT (Fig. 3b and 3c), we looked to see if a similar phenomenon was occurring in the COVID-19 patients from the MGH Emergency Department validation cohort. Indeed, in these 305 patients, plasma ADAMTS13 levels displayed a similarly robust inverse correlation with cardiac troponin I ($r=-0.4$, $p = 2 \times 10^{-14}$, Supplementary Fig. 6) and decreased further as COVID-19 progressed ($p = 2.2 \times 10^{-15}$; Fig. 4a). Moreover, lower ADAMTS13 levels on presentation were associated with overall disease severity ($p = 1.5 \times 10^{-6}$) and 28-day mortality ($p = 1.2 \times 10^{-6}$) (Fig. 4b and 4c).

To assess a potential causal role of decreased ADAMTS13 in myocardial injury, we performed Mendelian randomization (MR) analysis in 463,010 subjects in the UK BioBank using intronic cis-pQTLs, genetic determinants of ADAMTS13 protein levels that map to the gene itself. Since these genetic alleles are inherited independent of confounders, a positive association provides evidence that ADAMTS13 levels are in a causal pathway with cardiac injury, even outside the severe effects seen in TTP. Indeed, we found that lower genetically-determined levels of plasma ADAMTS13 were associated with higher likelihood of clinically diagnosed myocardial injury in a large, general population (IVW $\beta = -2.34 \times 10^{-4}$; $p = 6.4 \times 10^{-4}$) (Fig. 5 and Supplementary Fig. 7), suggesting that reduced ADAMTS13 levels increase vulnerability to cardiac injury.

To further investigate why circulating ADAMTS13 levels are lower in severe COVID-19 patients, we looked to see if ADAMTS13 gene expression changed in the SARS-CoV2 infected hamsters. Similar to humans, hamsters have severe endothelialitis associated with SARS-CoV2 infection^{9,22}. We found evidence of vascular thrombus formation in the lungs and small vessel fibrin deposition and cardiomyocyte degeneration consistent with microvascular compromise in infected animals (Fig. 6a-f). Compared to naïve controls, ADAMTS13 expression was 67% lower in SARS-CoV2 infected animals ($p_{\text{adj}}=1 \times 10^{-5}$; Fig. 6c), suggesting that at least part of the decrease in circulating ADAMTS13 seen in those with severe COVID-19 is through decreased synthesis of this anti-thrombotic protein. This was associated with a 3.8-fold increase in vWF expression ($p_{\text{adj}}=1.2 \times 10^{-18}$; Fig. 6c).

Increased TGF β superfamily signaling associated with the heart failure biomarker, NTproBNP, in COVID-19

Although cardiac microvascular thrombosis is likely a major contributor to myocardial injury in COVID-19, it is only identified in a subset of patients.^{11,12} Non-ischemic etiologies, such as right ventricular strain, myocarditis, and stress cardiomyopathy, are other sources of cardiac injury and dysfunction in COVID-19, which often result in high circulating levels of both cardiac troponins and the heart failure biomarker, NTproBNP.^{11,23,24} While ADAMTS13 showed an inverse relationship with NTproBNP, the correlation was modest ($r=-0.3$; $p = 0.03$, Fig. 3c), suggesting other processes are likely more substantial contributors to myocardial stress in COVID-19. After regression on NTproBNP, 526 proteins were significantly different. Of these, follistatin-like 3 (FSTL3), a marker of TGF β and Activin receptor signaling,²⁵ displayed

the most significant positive association with NTproBNP (β coefficient = 0.4; $p_{\text{adj}}=4.6 \times 10^{-7}$; Fig. 7a, Supplementary Table 13). FSTL3 levels correlated strongly with both NTproBNP and cardiac TnT ($r = 0.7$, $p < 0.001$ for both), and were markedly higher in both moderate and severe COVID-19 patients with cardiac involvement compared to their respective controls (Figs. 7b and 7c, Supplementary Tables 4 and 6).

The association between FSTL3 and NTproBNP levels robustly validated in the independent MGH Emergency Department cohort. FSTL3 levels showed similarly powerful correlations with NTproBNP ($r = 0.7$; $p < 2 \times 10^{-16}$) and cardiac TnT ($r = 0.6$; $p < 2 \times 10^{-16}$; Supplementary Fig. 9) and increased with disease duration ($p = 1.1 \times 10^{-9}$; Fig. 8a). Moreover, presenting FSTL3 levels strongly associated with both disease severity ($p = 4.0 \times 10^{-15}$) and 28-day mortality ($p = 4.8 \times 10^{-12}$) in COVID-19 (Figs. 8b and 8c).

MR analysis was unable to be performed for FSTL3 because only a single pQTL (rs12986335) has been identified for this protein and this pQTL did not reach genome-wide significance. Because FSTL3 is an indirect marker of increased TGF β and Activin receptor signaling rather than part of the causal pathway, we would not anticipate a causal relationship between FSTL3 and heart failure. Since expression of FSTL3 is induced by activation of TGF β and Activin receptors, which can be initiated by multiple ligands of the TGF β superfamily, including TGF β , Activins, bone morphogenic proteins (BMPs), and growth differentiation factors (GDFs),^{25,26} we looked to see which of these ligands might be contributing to the increased circulating FSTL3 observed in COVID-19. Fourteen of the relevant ligands are measured on the SOMAscan platform, and twelve of these positively correlated with FSTL3 (Supplementary Fig. 10). To determine which of these are likely responsible for the association of FSTL3 with increased myocardial stress in COVID-19, we exposed isolated cardiomyocytes to the various ligands, of which only Activins and TGF β robustly increased cardiomyocyte FSTL3 expression (Supplementary Fig. 11). Of these proteins, TGF β 1 was the most significantly increased in COVID-19 patients (74% higher than controls, $p_{\text{adj}}=7.2 \times 10^{-11}$), suggesting it may be the primary circulating ligand responsible for the increase in FSTL3 observed in COVID-19 patients with elevated NTproBNP. Although we were unable to determine if TGF β 1 expression is directly increased in the hearts of those with COVID-19, RNAseq profiles of lungs from hamsters infected with SARS-CoV2 indicated that TGF β 1 signaling is indeed upregulated in animals with severe infection (NES = 1.5; FDR q-value = 0.03, Supplementary Fig. 12).

Discussion

Cardiovascular complications are common in COVID-19 and are strongly associated with disease severity and mortality. Despite this, the principal drivers of cardiac injury and dysfunction remain unclear and no effective therapies for these complications of COVID-19 have been identified. To gain mechanistic insights into the underlying pathophysiology, we systematically compared circulating plasma proteins in controls and COVID-19 patients across a range of disease severity and cardiac involvement. Key findings from our 80 subject discovery cohort were not only validated in a distinct, longitudinal cohort of 305 COVID-19 patients, but also investigated in an experimental animal model of severe COVID-19. Our

analyses identified alterations in two biological pathways that strongly associated with cardiac injury in COVID-19: a reduction in the anti-thrombotic protein, ADAMTS13, and an increase in TGF β superfamily signaling, previously linked to cardiac dysfunction, injury, and fibrosis.^{25,27} These changes, along with an increase in senescence-associated secretory proteins, were also associated with disease severity and mortality. Notably, these pathways are potentially amenable to therapeutic intervention with agents already in clinical trials or FDA approved for other indications.^{28,29}

Particularly striking was the marked ADAMTS13 reduction that progressed with COVID-19 duration and severity. Of the 4996 protein analytes assessed in our discovery study, ADAMTS13 was not only the most significantly decreased protein in severe COVID-19, but also displayed the strongest inverse association with myocardial injury. Autopsies have found evidence of microvascular thrombosis in multiple organs, including the heart, in COVID-19 patients.^{9–12,30} Given its role in thrombotic microangiopathies,²¹ the possibility that an acquired ADAMTS13 deficiency or local imbalance with its substrate, vWF, could be driving thrombotic complications in COVID-19 has been raised.^{30–32} Our data provide new evidence supporting an important role for reduced ADAMTS13 in COVID-19 related myocardial injury. Mendelian randomization analysis of genetic variants within the ADAMTS13 gene strongly support a causal relationship between plasma ADAMTS13 protein levels and myocardial injury. Furthermore, the decreased mRNA expression of ADAMTS13 seen in the hamster model after SARS-CoV2 infection suggests that the decline in circulating ADAMTS13 in severe COVID-19 is at least partially due to a decrease in its synthesis. Given recent safety concerns of therapeutic systemic anticoagulation in critically ill COVID-19 patients³³, specifically replenishing ADAMTS13 in patients with low levels could provide a safer, targeted, and potentially more effective strategy for preventing vascular thrombosis in patients with severe COVID-19. Notably, recombinant ADAMTS13 has demonstrated safety in patients with congenital TTP,²⁸ and recent pilot testing of ex vivo plasma samples from patients with severe COVID-19 suggests it can effectively reduce the heightened vWF activity and increased ultra-high molecular weight vWF multimers observed in COVID-19³⁴. Based on our collective findings in humans and animals with COVID-19, we propose that targeted ADAMTS13 repletion warrants evaluation as a tailored approach to preventing myocardial injury and possibly other thromboembolic complications in patients with severe COVID-19 and reduced ADAMTS13 levels.

In addition to microvascular thrombosis, other non-ischemic etiologies, including stress cardiomyopathy and right ventricular strain, also contribute to myocardial necrosis in COVID-19, often resulting in substantial increases in not only cardiac troponins but also the heart failure biomarker, NTproBNP.^{11,23,24} Indeed in our analysis of the plasma proteome, we found the dominant proteomic signal associated with NTproBNP was not ADAMTS13, but rather FSTL3, a marker of TGF β superfamily signaling.²⁵ FSTL3 has been identified as one of only four circulating proteins (out of 1310 assayed) that potentially distinguishes between patients with acute stress cardiomyopathy in comparison to acute myocardial infarction.³⁵ It is possible that cardiac dysfunction driven by TGF β superfamily signaling is acutely reversible as seen in stress cardiomyopathy, consistent with some clinical observations in COVID-19.³⁶ However, the close association of TGF β superfamily signaling with fibrosis raises the possibility that

these pathways may also contribute to some of the long-term sequelae beginning to be appreciated in survivors of severe COVID-19. Importantly, multiple TGF β superfamily inhibitors, including those currently being investigated in clinical trials, have shown benefits in preclinical models of heart failure, as well as acute lung injury.^{25,37–39} While these data suggest that this class of reagents could attenuate cardiac and pulmonary injury in COVID-19, given the immunomodulatory roles of TGF β ,⁴⁰ careful patient selection and optimal timing of such interventions will be critical to maximizing therapeutic benefit while minimizing adverse effects on immune responses to the virus.

Lastly, our proteomics analysis detected a novel association between senescence associated secretory proteins, markers of biological aging, with disease severity and cardiac involvement in COVID-19. While age is a recognized risk factor for adverse COVID-19 outcomes, since study subjects in our discovery study were mostly age-matched, this finding suggests that *biological* aging may represent a more accurate marker of COVID-19 severity than *chronological* aging alone. Indeed, in the validation cohort, a subject's SASP profile on presentation was the most significant pathway associated with disease severity over the subsequent 28 days. Furthermore, the marked SASP enrichment seen in hamsters with severe COVID-19, suggests that SARS-CoV2 infection induces an increase in SASP production. This is consistent with the increase in circulating SASP proteins observed in patients with more severe COVID-19, which interestingly has also been linked to an increase in vascular thrombosis.⁴¹ Of course, these possibilities are not mutually exclusive. It is possible that pre-existing biological aging, reflected in circulating SASP proteins, puts patients at higher risk for severe COVID-19 and that SARS-CoV2 infection also induces cellular senescence, further increasing circulating SASP proteins in a positive feedback loop. While targeting senescence has been proposed as a potential therapeutic strategy for severe COVID-19^{42,43}, these are the first data to report an increase in SASP profiles in COVID-19 patients that tracks with disease severity. Understanding the role of senescence in COVID-19 pathophysiology could be important in the context of therapeutic development and as vaccine development and rollout continue over the coming year.⁴⁴

Several limitations of our study are worth noting. First, observational data cannot definitively establish causality. In the case of ADAMTS13, however, additional inferences from genetics strongly support a pathogenic role. Further studies of SARS-CoV2 infection in Syrian hamsters also mechanistically link viral infection to reduced ADAMTS13 expression. Second, the discovery study sample sizes were relatively small. In this context, the robust validation of our key findings in a larger dataset generated using an independent proteomic technology is reassuring. Finally, while promising candidates were identified that might be targeted to mitigate COVID-19 cardiac complications, these hypotheses require rigorous additional testing. Importantly, our clinical observations strongly resonate with findings in the hamster model of severe COVID-19, further supporting an important role of these processes in COVID-19 pathophysiology. These findings also suggest this model could provide a preclinical tool for testing the safety and therapeutic efficacy of currently available reagents targeting these candidates as a prelude to clinical trials.

In summary, systematic analysis of circulating plasma proteins revealed important insights in COVID-19 cardiovascular pathophysiology and provides a foundation for novel therapeutic approaches to prevent or treat cardiac complications of COVID-19. Further investigation is warranted to determine if restoring ADAMTS13 levels, inhibiting TGF β superfamily signaling, or modulating senescence can mitigate cardiovascular complications and improve outcomes in COVID-19 patients.

Methods

Discovery Study:

To identify proteins that change with cardiac involvement in COVID-19, a case-control plasma proteomics study was performed in 80 subjects whose plasma samples were available from the multi-institutional Massachusetts Consortium on Pathogen Readiness and the Mass General Brigham (MGB) Biobank. COVID-19 subjects were recruited and plasma samples were collected with informed consent and IRB approval between March and June 2020 at Massachusetts General Hospital and Brigham and Women's Hospital in Boston, MA. Subjects were chosen based on data from their electronic medical records, to fill five pre-specified groups representing a range of disease severity and cardiac involvement. To reduce the confounding influence of factors previously linked to COVID-19 severity, groups were matched as much as possible for age, sex, and race. Patients enrolled in immunomodulator clinical trials or receiving such agents off-label were excluded. Study groups included non-COVID-19 controls; COVID-19 patients with moderate disease (hospitalized, but not requiring intensive care unit [ICU] level of care) with or without cardiac involvement; and COVID-19 patients with severe disease (requiring ICU care) with low or high degrees of cardiac involvement (Table 1). In patients with moderate COVID-19, cardiac involvement was defined as at least one of the following near time of plasma collection: a high-sensitivity cardiac troponin T (hsTnT) > 14ng/L, N-terminal pro-B natriuretic peptide (NTproBNP) > 1,800pg/ml, and/or cardiac dysfunction documented by transthoracic echocardiography (left ventricular ejection fraction [LVEF] < 50%, regional wall motion abnormality, right ventricular systolic dysfunction, or > 25% relative decrease from prior LVEF). The hsTnT threshold of 14 ng/L is consistent with the Fourth Universal Definition of Myocardial Infarction,⁴⁵ which defines myocardial injury as a troponin concentration greater than the 99th percentile upper reference limit. For severe COVID-19 patients in the ICU, who have a high prevalence of mild troponin elevation, we used a hsTnT threshold of 20 ng/L to distinguish between low and higher levels of myocardial injury, while the remainder of the criteria were the same. Clinical outcomes included intubation, vasopressor requirement, neuromuscular blockade use, sedation, renal replacement therapy (RRT), pulmonary embolism (PE), deep venous thrombosis (DVT), and in-hospital mortality.

Plasma Proteomic Profiling

All blood samples obtained from subjects in the discovery study were anticoagulated with EDTA and collected plasma was frozen at -80C and underwent two freeze-thaw cycles before proteomic analysis. An aptamer-based proteomics platform (version 4; Somalogic) was used to measure relative levels of 4996 analytes, corresponding to 4730 distinct human proteins.

Clinical Validation Study:

Key findings in the discovery proteomics study were validated in a publicly available, independent plasma proteomics dataset from the MGH Emergency Department COVID-19 Cohort (Filbin, Goldberg, Hacohen) analyzed using Olink, an antibody-based proteomics platform⁴⁶. This cohort included 305 COVID-19 patients. Patients who were hospitalized had serial plasma samples collected during their hospitalization on days 0, 3, and 7. For 36 patients, an additional sample was collected on day E, corresponding to a significant clinical deterioration event. Maximum disease severity for each subject within 28 days of presentation was determined according to the World Health Organization (WHO) Ordinal Outcomes Scale (1 = death within 28 days, 2 = Intubated, ventilated, survived to 28 days, 3 = Non-invasive ventilation or high-flow nasal cannula, 4 = Hospitalized, supplementary O2 required; 5 = Hospitalized, no supplementary O2 required; 6 = Not hospitalized).

Mendelian Randomization of ADAMTS13 cis-pQTLs:

Automated 2-sample Mendelian randomization (MR) was performed through an open-source application, MR-Base (www.mrbase.org), that systematically supports causal inference interrogation with summary-level data⁴⁷. A multivariant instrument was constructed to genetically estimate protein levels of ADAMTS13 using locus-wide significant pQTLs acquired from PhenoScanner (www.phenoscanter.com). All locus wide intronic significant pQTLs ($p < 3.88 \times 10^{-4}$) were ranked by effect size and pruned for independence ($R^2 < 0.1$). Rare variants were excluded ($MAF > 0.01$). For each direction of influence, we combined the MR effect estimates from each instrument SNP using inverse variance weighted (IVW) meta-analysis to obtain a meta-analytic estimate. Sensitivity analyses were performed through the standard and additional evaluation of a weighted median and an MR-Egger estimate. Given an experimentally derived hypothesis that COVID-19 results in cardiac injury without infarction, we sought the most proximate ICD10 code for acute myocardial injury (ICD: I24.8, Other forms of acute ischemic heart disease). Summary statistics were acquired from UKB-b:11309 ($n = 463,010$ with the dataset containing 269 cases and 462,741 controls). Outcome summary statistics were accessed 9/20/2020 in MR-Base. See Supplementary Fig. 1 for a detailed flow diagram of the MR procedure used.

Golden Syrian Hamster COVID-19 Model

Cardiac and pulmonary tissue from six golden Syrian hamsters (Envigo), ages 10–12 week old, from our prior work²² were used to further investigate candidate targets from the human discovery study. All animals were housed at Bioqual and studies were approved by their Institutional Animal Care and Use Committee. Animals were divided into two groups, naïve (uninfected) controls and SARS-CoV2 infected ($n = 3/\text{group}$). SARS-CoV2 infection was performed using previously published methods²². Briefly, animals in the infected group were each challenged with 5.0×10^5 TCID₅₀ (6×10^8 vp, 5.5×10^4 plaque-forming units (PFU)) SARS-CoV2, derived from USA-WA1/2020 (NR-52281, BEI Resources). Each animal in the infected group received 100 ml virus via intranasal administration. On day 4 post-infection, all animals were euthanized. Heart and lung samples were either fixed in 4% paraformaldehyde for histologic staining or homogenized in QIAzol (Qiagen) and stored at -80C for RNA sequencing. Histological tissue processing, Carstairs' method, and hematoxylin and eosin staining protocols were performed using previously published methods^{22,48}. RNA was extracted from frozen lung tissue using the

miRNeasy kit (Qiagen) with on-column DNase digestion, and quality was assessed using an Agilent Bioanalyzer. Library preparation was done using the SMARTer Stranded Total RNA-Seq V2 Pico Input Mammalian kit (Taara Bio). Libraries were validated with an Agilent 4200 TapeStation, and sequenced on an Illumina NovaSeq6000 at 100SR, targeting 25–30 million reads per sample.

FSTL3 Induction in Isolated Cardiomyocytes

Neonatal rat cardiomyocyte isolation, culture, and gene expression studies were performed using previously published methods²⁵. Briefly, isolated cardiomyocytes were cultured in serum-free medium and incubated for 18 hours with 10ng/ml of various recombinant ligand proteins (Peprotech or R&D Systems) known to bind TGF β receptors or Activin type II receptors (ActRII). RNA was extracted using Trizol, and polymerase chain reaction was done using SYBR green and standard amplification protocols. Relative changes in gene expression were measured using the $\Delta\Delta CT$ method.

Bioinformatic and Statistical Analyses

For analysis of the SOMAscan proteomics discovery study, median normalized relative abundances of the 4996 analytes were imported into *R* (v3.6.1) using the *SomaDataIO* package. Principal component analysis (PCA) was performed on log-transformed values using *R*'s *prcomp* function, differential protein abundance using *limma* (version 3.40.6), and protein enrichment using *clusterProfiler* (version 3.12.0). Pathway analysis was done using Gene Ontology data (MSigDB), appended with two curated senescence associated secretory phenotype (SASP) pathways. For gene-set enrichment analyses (GSEA), proteins were ranked by t-statistic and 50,000 permutations used to compute the nominal enrichment p-values. For all analyses, p-values were adjusted for multiple comparisons using the Benjamini & Hochberg method.

For validation using the data released by Filbin and colleagues⁴⁶, we obtained Olink Normalized Protein eXpression (NPX) data and associated patient metadata from www.olink.com/mgh-covid-study. Of the 383 individuals included in this study, we removed patients without documented COVID-19 positivity, leaving 305 patients. In assessing the relationships of ADAMTS13 and FSTL3 with days post diagnosis, WHO severity, and 28-day survival we applied linear regression models and provide the overall model fit. For the regressions on WHO severity and 28-day survival we used only protein abundances in NPX units from D0 patient samples.

Between-group comparisons in patient demographics and outcomes were examined using analysis of variance (ANOVA), followed by pairwise comparisons using chi-squared, t-tests, or Fisher's exact tests as appropriate between those with and without COVID-19, as well as those with and without cardiac involvement within each disease severity stratum. Pearson correlations were used to measure correlation of candidate proteins with cardiac biomarkers.

Analysis of the golden Syrian hamster lung RNA sequence data was done using STAR version 2.7.3a with the MesAur1.0 (GCF_000349665.1) assembly and annotation of the hamster downloaded from NCBI. Transcript abundance estimates were calculated internal to the STAR aligner using the algorithm of

htseq-count. DESeq2 was used for normalization, producing both a raw and normalized read count table. Differential expression at the gene level were performed by DESeq2 implemented in the DESeq2 R package. An adjusted p-value < 0.05 was used to determine genes that were significantly upregulated or downregulated by SARS-CoV2 at day 4 post challenge compared to naïve controls using the Benajmini & Hochberg method.

Declarations

DATA AVAILABILITY:

All data that support the findings of this study are included in the published article and its supplementary information files. The datasets during the current study are available from the corresponding author on reasonable request.

ACKNOWLEDGEMENTS:

The authors acknowledge the Massachusetts Consortium on Pathogen Readiness (MassCPR) and the Mass General Brigham Biobank for provision of samples, technical assistance and consultation. They are appreciative of Cesar Piedra-Mora's assistance with histology. This work was supported by the NIH (R01AG061034 and R35HL15531 (A.R.); R01HL092577, R01HL128914, and K24HL105780 (P.T.E); R01HL134893, R01HL140224, K24HL153669 (J.E.H.); T32HL094301 (B.W.); K08HL140200 (J.R.); and K76AG064328 (J.D.R)), the Fondation Leducq (14CVD01 (P.T.E.)), the American Heart Association (18SFRN34110082 (P.T.E.)), a Sarnoff Cardiovascular Research Foundation Fellowship award (L.E.T.), the Fred and Ines Yeatts Fund for Innovative Research (J.D.R), the Hassenfeld Scholars Award (J.D.R.), Fast Grants, Emergent Ventures, Mercatus Center at George Mason University (A.J.M.), and a research grant from Bayer AG to the Broad Institute (P.T.E and J.E.H).

AUTHOR CONTRIBUTIONS:

J.D.R. and A.R. designed the study. J.D.R., J.R., B.W., L.E.T., M.H.H., T.W.C., M.F.D., A.R. identified study subjects and acquired the relevant clinical data. J.D.R. and C.P. prepared COVID-19 plasma samples for proteomics analysis. R.K. J.N.M., J.E.H., and J.R. performed the statistical analyses on the clinical datasets. J.S.G. and B.A. performed the MR analyses. C.P., A.Y., P.X., C.C., P.T.C assisted with the cardiomyocyte work and analyses. M.B., D.H.B. performed the hamster studies and analyses; A.J.M. and S.D. performed histopathological analyses in hamsters. J.D.R., R.K., J.S.G., and A.R. wrote the manuscript. All authors provided feedback on the manuscript.

COMPETING INTERESTS:

A.R. and J.D.R. are co-inventors on a relevant patent, Methods for preventing and treating heart disease\ (WO2018175460A1). P.T.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and he has served on advisory boards or consulted

for Bayer AG, Quest Diagnostics, MyoKardia and Novartis. J.E.H. has received research grants from Bayer AG, Gilead Sciences, and research supplies from EcoNugenics.

References

- 1 World Health Organization. *WHO coronavirus disease (covid-19) dashboard*, <<https://covid19.who.int/>> (2021, May 17).
- 2 Guo, T. *et al.* Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* **5**, 811-818, doi:10.1001/jamacardio.2020.1017 (2020).
- 3 Shi, S. *et al.* Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol* **5**, 802-810, doi:10.1001/jamacardio.2020.0950 (2020).
- 4 Lala, A. *et al.* Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. *J Am Coll Cardiol* **76**, 533-546, doi:10.1016/j.jacc.2020.06.007 (2020).
- 5 Lombardi, C. M. *et al.* Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. *JAMA Cardiol* **5**, 1274-1280, doi:10.1001/jamacardio.2020.3538 (2020).
- 6 Smilowitz, N. R. *et al.* Myocardial Injury in Adults Hospitalized With COVID-19. *Circulation* **142**, 2393-2395, doi:10.1161/CIRCULATIONAHA.120.050434 (2020).
- 7 Bilaloglu, S. *et al.* Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. *JAMA* **324**, 799-801, doi:10.1001/jama.2020.13372 (2020).
- 8 Rey, J. R. *et al.* Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. *Eur J Heart Fail*, doi:10.1002/ehhf.1990 (2020).
- 9 Varga, Z. *et al.* Endothelial cell infection and endotheliitis in COVID-19. *Lancet* **395**, 1417-1418, doi:10.1016/S0140-6736(20)30937-5 (2020).
- 10 Fox, S. E. *et al.* Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* **8**, 681-686, doi:10.1016/S2213-2600(20)30243-5 (2020).
- 11 Basso, C. *et al.* Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. *Eur Heart J* **41**, 3827-3835, doi:10.1093/eurheartj/ehaa664 (2020).
- 12 Halushka, M. K. & Vander Heide, R. S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. *Cardiovasc Pathol* **50**, 107300, doi:10.1016/j.carpath.2020.107300 (2020).

- 13 Pellegrini, D. *et al.* Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. *Circulation* **143**, 1031-1042, doi:10.1161/CIRCULATIONAHA.120.051828 (2021).
- 14 Sandoval, Y., Januzzi, J. L., Jr. & Jaffe, A. S. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. *J Am Coll Cardiol* **76**, 1244-1258, doi:10.1016/j.jacc.2020.06.068 (2020).
- 15 Giustino, G. *et al.* Characterization of Myocardial Injury in Patients With COVID-19. *J Am Coll Cardiol* **76**, 2043-2055, doi:10.1016/j.jacc.2020.08.069 (2020).
- 16 Basisty, N. *et al.* A proteomic atlas of senescence-associated secretomes for aging biomarker development. *PLoS Biol* **18**, e3000599, doi:10.1371/journal.pbio.3000599 (2020).
- 17 Leppkes, M. *et al.* Vascular occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine* **58**, 102925, doi:10.1016/j.ebiom.2020.102925 (2020).
- 18 Cash, H. L., Whitham, C. V., Behrendt, C. L. & Hooper, L. V. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. *Science* **313**, 1126-1130, doi:10.1126/science.1127119 (2006).
- 19 Choi, S. M. *et al.* Innate Stat3-mediated induction of the antimicrobial protein Reg3gamma is required for host defense against MRSA pneumonia. *J Exp Med* **210**, 551-561, doi:10.1084/jem.20120260 (2013).
- 20 Cremer, H. *et al.* Inactivation of the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning. *Nature* **367**, 455-459, doi:10.1038/367455a0 (1994).
- 21 Levy, G. G. *et al.* Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature* **413**, 488-494, doi:10.1038/35097008 (2001).
- 22 Tostanoski, L. H. *et al.* Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. *Nat Med* **26**, 1694-1700, doi:10.1038/s41591-020-1070-6 (2020).
- 23 Dweck, M. R. *et al.* Global evaluation of echocardiography in patients with COVID-19. *Eur Heart J Cardiovasc Imaging* **21**, 949-958, doi:10.1093/ehjci/jeaa178 (2020).
- 24 Giustino, G. *et al.* Takotsubo Cardiomyopathy in COVID-19. *J Am Coll Cardiol* **76**, 628-629, doi:10.1016/j.jacc.2020.05.068 (2020).
- 25 Roh, J. D. *et al.* Activin type II receptor signaling in cardiac aging and heart failure. *Sci Transl Med* **11**, doi:10.1126/scitranslmed.aau8680 (2019).
- 26 Koncarevic, A. *et al.* A novel therapeutic approach to treating obesity through modulation of TGFbeta signaling. *Endocrinology* **153**, 3133-3146, doi:10.1210/en.2012-1016 (2012).

- 27 Dobaczewski, M., Chen, W. & Frangogiannis, N. G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. *J Mol Cell Cardiol* **51**, 600-606, doi:10.1016/j.yjmcc.2010.10.033 (2011).
- 28 Scully, M. *et al.* Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. *Blood* **130**, 2055-2063, doi:10.1182/blood-2017-06-788026 (2017).
- 29 Fenaux, P. *et al.* Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *N Engl J Med* **382**, 140-151, doi:10.1056/NEJMoa1908892 (2020).
- 30 Rovas, A. *et al.* Microvascular dysfunction in COVID-19: the MYSTIC study. *Angiogenesis*, doi:10.1007/s10456-020-09753-7 (2020).
- 31 Bazzan, M. *et al.* Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. *Intern Emerg Med* **15**, 861-863, doi:10.1007/s11739-020-02394-0 (2020).
- 32 Tiscia, G. L. *et al.* Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients. *TH Open* **4**, e203-e206, doi:10.1055/s-0040-1716379 (2020).
- 33 Investigators, I. *et al.* Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. *JAMA*, doi:10.1001/jama.2021.4152 (2021).
- 34 Turecek, P. L. *et al.* Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. *Thromb Res* **201**, 100-112, doi:10.1016/j.thromres.2021.02.012 (2021).
- 35 Fitzgibbons, T. P. *et al.* Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy. *Front Cardiovasc Med* **4**, 49, doi:10.3389/fcvm.2017.00049 (2017).
- 36 Newton-Cheh, C. *et al.* Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock. *N Engl J Med* **383**, 475-484, doi:10.1056/NEJMcpc2004975 (2020).
- 37 Yung, L. M. *et al.* ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. *Sci Transl Med* **12**, doi:10.1126/scitranslmed.aaz5660 (2020).
- 38 Apostolou, E. *et al.* Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. *Am J Respir Crit Care Med* **185**, 382-391, doi:10.1164/rccm.201105-0784OC (2012).
- 39 Pittet, J. F. *et al.* TGF-beta is a critical mediator of acute lung injury. *J Clin Invest* **107**, 1537-1544, doi:10.1172/JCI11963 (2001).

- 40 Travis, M. A. & Sheppard, D. TGF-beta activation and function in immunity. *Annu Rev Immunol* **32**, 51-82, doi:10.1146/annurev-immunol-032713-120257 (2014).
- 41 Wiley, C. D. *et al.* SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells. *Cell Rep* **28**, 3329-3337 e3325, doi:10.1016/j.celrep.2019.08.049 (2019).
- 42 Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. *Science* **369**, 256-257, doi:10.1126/science.abb0762 (2020).
- 43 Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G. & Demaria, M. Cellular senescence as a potential mediator of COVID-19 severity in the elderly. *Aging Cell* **19**, e13237, doi:10.1111/accel.13237 (2020).
- 44 Cox, L. S. *et al.* Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. *Lancet Healthy Longev* **1**, e55-e57, doi:10.1016/S2666-7568(20)30011-8 (2020).
- 45 Thygesen, K. *et al.* Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol* **72**, 2231-2264, doi:10.1016/j.jacc.2018.08.1038 (2018).
- 46 Filbin, M. R. *et al.* Longitudinal proteomic analysis of plasma from patients with severe COVID-19 reveal patient survival-associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med*, 100287, doi:10.1016/j.xcrm.2021.100287 (2021).
- 47 Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**, doi:10.7554/eLife.34408 (2018).
- 48 Aid, M. *et al.* Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. *Cell* **183**, 1354-1366 e1313, doi:10.1016/j.cell.2020.10.005 (2020).

Tables

Table 1: Clinical Characteristics of Subjects in Discovery Study

COVID-	Moderate COVID-19		Severe COVID-19		P _{ANOVA}	
Control (N=26)	CV- (N=13)	CV+ (N=12)	CV _{low} (N=14)	CV _{high} (N=15)		
Age, years	62 (10)	63 (8)	72 (16)	62 (12)	63 (10)	0.11
Women	10 (39%)	9 (69%)	6 (50%)	4 (29%)	4 (27%)	0.18
Race	*					0.29
White	19 (73%)	6 (46%)	8 (67%)	5 (36%)	7 (47%)	
Black	1 (4%)	2 (15%)	2 (17%)	4 (29%)	5 (33%)	
Hispanic	2 (8%)	4 (31%)	2 (17%)	4 (29%)	3 (20%)	
Other	4 (15%)	1 (8%)	0 (0%)	1 (7%)	0 (0%)	
BMI, kg/m ²	33.1 (4.1)*	27.6 (4.1)	31.1 (8.7)	27.9 (4.3)	31.9 (10.3)	0.06
Past Medical History						
Pulmonary disease	8 (31%)	2 (15%)	3 (25%)	4 (29%)	3 (20%)	0.85
COPD	0(0%)	1(8%)	0 (0%)	1(7%)	2 (14%)	0.34
Asthma	1 (4%)	2 (15%)	2 (17%)	2 (14%)	1 (7%)	0.63
ILD	0 (0%)	0 (0%)	1 (8%)	0(0%)	0 (0%)	0.22
CAD	0(0%)*	1 (8%)	5 (42%)	1 (7%)	3 (20%)	0.006
MI	0 (0%)	0 (0%)	3(25%)	0 (0%)	2(13%)	0.02
Stroke	0 (0%)	1 (8%)	1 (8%)	0 (0%)	2 (13%)	0.31
Hypertension	13 (50%)	6 (46%)	10 (83%)	10 (71%)	9 (60%)	0.23
Hyperlipidemia	11 (42%)	8 (62%)	7 (58%)	7 (50%)	9 (60%)	0.73
Diabetes Mellitus	1 (4%)*	2(15%)	6 (50%)	6 (43%)	7 (47%)	0.003
Cancer	0 (0%)*	3 (23%)	3 (25%)	0 (0%)	6 (40%)*	0.003
Liver Disease	2 (8%)	4 (31%)	1 (8%)	2 (14%)	2 (13%)	0.37
Kidney Disease	0 (0%)*	1 (8%)	6 (50%) *	1 (7%)	1 (7%)	<0.0001
Baseline Medications						
Anticoagulation	1 (4%)	0 (0%)	5 (42%)*	0 (0%)	3 (20%)	0.002
NSAID	9 (35%)	3 (23%)	5 (38%)	3 (21%)	8 (53%)	0.36
Statin	11 (42%)	5 (38%)	7 (58%)	6 (43%)	6 (40%)	0.86
Immunosuppression	0 (0%)	0 (0%)	1(8%)	1 (7%)	1 (7%)	0.56

Values are mean (SD) or n (%). P_{ANOVA} tested differences between groups. * indicates P<0.05 on Fisher exact pairwise testing between COVID-19 patients and COVID-19 negative controls – groupings or between CV (+/-) or CV (low/high) within moderate and severe COVID-19 groups, respectively. CV = cardiac involvement.

Figures

Figure 1

Senescence associated secretory phenotype is associated with COVID-19 severity and cardiac involvement. a) Principal component analysis of the discovery proteomics study with boxplots displaying unsupervised clustering of the 80 patient plasma samples based on PC1 proteins. b) Venn diagram displaying overlapping pathways associated with increasing COVID-19 severity in the discovery and validation cohorts. In the discovery cohort, enrichment analysis was done with PC1 proteins (Supplementary Table 2). In the validation cohort, pathway analysis was performed using Day 0 proteomic profiles regressed on maximum WHO disease severity per patient (Supplementary Table 8). c) Heat maps displaying differential expression of the 50 most significantly regulated genes in the SASP-1 or SASP-2 gene sets in lungs from hamsters infected with SARS-CoV2 versus naïve controls. Tissue samples were collected four days after infection. n=3/group. SASP = senescence associated secretory phenotype.

Figure 2

Differentially expressed plasma proteins associated with COVID-19 infection and disease severity. a) Volcano plot displaying differentially expressed plasma proteins in the discovery study when comparative analysis was done between COVID-19 patients (n=54) versus controls (n=26). b) Volcano plot displaying differentially expressed plasma proteins in the discovery study when comparing COVID-19 patients with moderate (n=25) versus severe (n=29) disease. Proteins with significant ($\text{padj} < 0.05$) differences in abundance (non-significant proteins colored black) with an absolute change greater than 1.5-fold are colored red (proteins with more modest fold-change are colored blue). For all analyses, p-values were adjusted for multiple hypothesis testing using the Benjamini & Hochberg method.

Figure 4

Association of lower ADAMTS13 levels with disease severity and mortality in COVID-19. Boxplots of ADAMTS13 plasma levels in the MGH Emergency Department validation cohort (n=305 COVID-19 patients) according to a) days from initial presentation or at event, E, marking significant clinical deterioration, b) maximum COVID-19 severity (WHO classification), or c) 28-day survival. Boxplots represent median with inter-quartile range. NPX = normalized protein expression.

Figure 5

Mendelian randomization analysis of cis-pQTLs in ADAMTS13 gene infers causality in myocardial injury. Scatterplot of SNP effects on ADAMTS13 plasma levels (pQTLs) and clinically diagnosed myocardial injury in the UK Biobank general population sample (n=463,010; 269 cases and 462,741 controls). The slope of each line corresponds to the estimated Mendelian randomization effect per method. (Light blue= Inverse variance-weighted method; Dark blue= Weighted median method; Green= MR Egger method). This demonstrates that genetically determined decreases in ADAMTS13 levels are quantitatively associated with increasing risk of myocardial injury, and support a causal role of ADAMTS13 in this context.

Figure 6

Pulmonary and cardiac vascular thrombus formation and decreased ADAMTS13 expression in SARS-CoV2 infected Syrian hamsters. Hamsters were infected with 5x10⁵ TCID₅₀ SARS CoV-2 and euthanized on day 4 following challenge. a) thrombus, pulmonary vein. b) endothelialitis, pulmonary vein. c) endothelialitis, pulmonary artery. d) fibrin deposition along endothelium, cardiac vein. e) fibrin deposition, cardiac artery with adjacent myodegeneration. f) focal myocarditis and myodegeneration. (a,c) Carstairs stain. (b, c, e, f) hematoxylin and eosin. Scale bars= 20 microns. g) Relative change in mRNA levels of ADAMTS13 and its substrate, vWF, in lung tissue from hamsters infected with SARS-CoV2 (n=3) compared to naive uninfected controls (n=3). Tissues samples were collected at four days post-infection and mRNA levels quantified used bulk RNAseq. P-values were adjusted for multiple hypothesis testing using the Benjamini & Hochberg method.

Figure 8

Association of TGF β superfamily signaling with disease severity and mortality in COVID-19. Boxplots of FSTL3 levels in the MGH Emergency Department validation cohort according to a) time from clinical presentation in days or at event, E, marked by significant clinical deterioration, b) maximum COVID-19 severity by WHO classification, or c) 28-day survival. Boxplots represent median with inter-quartile range. NPX = normalized protein expression.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [RohetalNatCommunSupplementalTables213.xlsx](#)
- [RohetalNatCommunSupplemental.docx](#)